Spectris plc has a fifty-two week low of GBX 2,370 ($29.29) and a fifty-two week high of GBX 3,730 ($46.09). The company has a debt-to-equity ratio of 4.37, a current ratio of 2.36 and a quick ...

CAMBRIDGE, Mass., February 11, 2025--(BUSINESS WIRE)--Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, today announced the publication ...

The study, titled “CSF Proteomics Reveals Changes in Myelin and Synaptic Biology Following Spectris™ Treatment,” offers compelling evidence of Spectris™’ ability to modulate core ...

Jefferies analyst Andrew Douglas has maintained their bullish stance on SXS stock, giving a Buy rating on January 21. Andrew Douglas’s rating is based on the recent trading update from Spectris ...

The study, titled "CSF Proteomics Reveals Changes in Myelin and Synaptic Biology Following Spectris™ Treatment," offers compelling evidence of Spectris™’ ability to modulate core biological pathways ...

Using the 2 Stage Free Cash Flow to Equity, Spectris fair value estimate is UK£42.80 Spectris is estimated to be 30% undervalued based on current share price of UK£29.82 The UK£31.05 analyst ...

Shares in Spectris have delivered a thoroughly disappointing return since this column first recommended them in November 2022. The precision instruments business, which provides data and insights ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Barclays cuts Admiral price target to 3,153 (3,326) pence - 'overweight' Deutsche Bank raises Schroders price target to 375 (350) pence - 'hold' Deutsche Bank raises AstraZeneca price target to ...